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Abstract 29 
Cachexia is a life-threatening complication of cancer traditionally characterized by weight loss and muscle 30 
dysfunction.  Cachexia, however, is a systemic disease that also involves remodeling of non-muscle organs.  31 
The liver exerts major control over systemic metabolism yet its role in cancer cachexia is not well-understood.  32 
To advance the understanding of how the liver contributes to cancer cachexia, we used quantitative 33 
proteomics and bioinformatics to identify hepatic pathways and cellular processes dysregulated in mice with 34 
moderate and severe colon-26 tumor-induced cachexia.  ~300 differentially expressed proteins identified 35 
during the induction of moderate cachexia were also differentially regulated in the transition to severe 36 
cachexia.  KEGG pathways enrichment revealed representation by oxidative phosphorylation, indicating 37 
altered hepatic mitochondrial function as a common feature across cachexia severity.  Glycogen catabolism 38 
was also observed in cachexic livers along with decreased pyruvate dehydrogenase protein X component 39 
(Pdhx), increased lactate dehydrogenase A chain (Ldha), and increased lactate transporter Mct1.  Together 40 
this suggests altered lactate metabolism and transport in cachexic livers, which may contribute to energetically 41 
inefficient inter-organ lactate cycling.  Acyl-CoA synthetase-1 (ACSL1), known for activating long-chain fatty 42 
acids, was decreased in moderate and severe cachexia based on LC-MS/MS analysis and immunoblotting.  43 
ACSL1 showed strong linear relationships with percent body weight change and muscle fiber size (R2=0.73-44 
0.76, P<0.01).  Mitochondrial coupling efficiency, which is compromised in cachexic livers to potentially 45 
increase energy expenditure and weight loss, also showed a linear relationship with ACSL1.  Findings suggest 46 
altered mitochondrial and substrate metabolism of the liver in cancer cachexia, and possible hepatic targets for 47 
intervention. 48 
 49 
  50 
 51 
 52 
 53 
 54 
 55 
Keywords:  mitochondrial function, TMT, quantitative proteomics, bioinformatics, STRING 56 
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Introduction 57 
Cancer cachexia is a life-threatening condition in which tumor-induced metabolic abnormalities lead to 58 
severe weight loss, skeletal muscle atrophy, and intolerance to anti-cancer treatment (10, 11).  Approximately 59 
half of all cancer patients experience cachexia, with incidence rising to ~80% in advanced cancer patients (33).  60 
Although cachexia is believed to be directly responsible for ~20% of cancer-related deaths, this debilitating 61 
complication remains an under-appreciated issue in oncology (33).  Nutritional support does not ameliorate 62 
cachexia due to the metabolic abnormalities present, and approved treatments options are currently 63 
unavailable, contributing to significant frustration among patients and their family members (10, 26).   64 
While skeletal muscle remains the most widely studied organ in cancer cachexia, increasing attention 65 
has been devoted to the mechanistic roles of other organs such as adipose, bone, brain, heart, and liver, 66 
reflecting a greater appreciation for the systemic nature of the disease (25).  The multi-organ involvement 67 
highlights the significant complexities of tumor-induced cachexia, and unraveling the root cause remains a 68 
challenge.  Omics technologies offer a global, unbiased approach to identify regulators of the cachexic 69 
phenotype (15, 31).  In various omics platforms, mechanisms distinguishing cachexic from healthy muscle 70 
have been identified in patient-derived tissues, pre-clinical models, and myotubes treated with tumor-71 
conditioned media (5, 14, 27-29).  These investigations report that cachexic skeletal muscle displays enriched 72 
ubiquitin-dependent protein degradation, loss of sarcomere structure, mitochondrial dysfunction, disrupted 73 
energy metabolism, and energetic stress, offering an explanation for skeletal muscle atrophy and the symptom 74 
of fatigue.   75 
 In contrast to skeletal muscle, the liver has been relatively unexplored in cancer cachexia despite 76 
exerting major control over systemic metabolism.  Several lines of limited evidence point to an influential role of 77 
the liver in cachexia-associated muscle atrophy and weight loss.  First, the liver participates in the systemic 78 
acute phase response to disease and infection by synthesizing acute phase proteins.  In order to support the 79 
increased demand for acute phase protein synthesis, amino acids are mobilized and released from skeletal 80 
muscle, contributing to tumor-induced muscle atrophy (6).  It is also suggested that uncoupling of mitochondrial 81 
oxidative phosphorylation (OXPHOS) in the liver in cancer cachexia contributes to inefficiency, heat 82 
production, increased metabolic rate, and weight loss (9, 25).  Indeed, a recent report found cachexic liver 83 
mitochondria to have reduced respiratory control ratio and increased LEAK respiration, suggesting impaired 84 
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OXPHOS coupling efficiency (18).  Greater hepatic heat production arising from mitochondrial uncoupling may 85 
increase whole body resting energy expenditure and contribute to unintended weight loss.  Lastly, cachexic 86 
livers may demonstrate increased gluconeogenesis supported by amino acids mobilized from the catabolism of 87 
skeletal muscle (17).  When hepatic gluconeogenesis was normalized using a PPARα agonist, tumor-bearing 88 
mice were protected against weight loss and muscle atrophy (17), implying that hallmark features of cancer 89 
cachexia can be mitigated by targeting hepatic metabolism. 90 
To identify hepatic pathways and cellular processes associated with cancer cachexia, as well as 91 
candidate hepatic targets for therapeutic intervention, unbiased omics analysis of cachexic liver tissues are 92 
warranted.  Here we used tandem mass tag (TMT)-based quantitative proteomics to identify differentially 93 
expressed hepatic proteins and dysregulated metabolic pathways during the induction and progression of 94 
colon-26 tumor-induced cachexia, a well-established pre-clinical mouse model (7).  Bioinformatics identified 95 
functional enrichments associated with the different degrees of cachexia severity, while findings were validated 96 
with immunoblotting and biochemical assays. 97 
 98 
Methods 99 
Animals and design 100 
Ten-week-old Balb/c males (Envigo) were randomly assigned to receive either an injection of sterile 101 
PBS or colon-26 (C26) tumor cells.  A tumor growth period of three weeks is typically allowed to elapse before 102 
tissue collection in order for hallmark features of cachexia to occur (i.e. weight loss, muscle atrophy).  To 103 
evaluate mechanisms of cachexia severity, tissue was collected from C26 mice between days 14-21 after 104 
tumor cell injection, and classified according to weight loss in accordance with previous literature (6, 34).  The 105 
4 groups included: 1) Tumor-free, weight-stable mice that were PBS injected (PBS-WS, n=4), 2) C26 mice with 106 
confirmed tumors that did not exhibit weight loss and were therefore weight-stable (C26-WS, n=6), 3) C26 107 
mice with moderate cachexia (10% weight loss; C26-MOD, n=7), and 4) C26 mice with severe cachexia (≥20% 108 
weight loss; C26-SEV, n=6).  These classifications were adapted from previous pre-clinical investigations (6, 109 
34).  Weight loss for each mouse was determined by the percentage change between carcass weight (i.e. 110 
tumor-free body weight) and body weight recorded on the day of cell injection.  Mice were individually housed, 111 
provided ad libitum water and food (5L0D, protein 29% fat 13%, carbohydrate 58%, PicoLab Laboratory 112 
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Rodent Diet), and maintained on a 12:12 hr light:dark cycle.  C26 mice may or may not exhibit reduced food 113 
intake depending on the source of the C26 cells and the phenotype it generates when transplanted in vivo (23).  114 
The C26 cells in this study were obtained from a cell bank that others have used to demonstrate no significant 115 
effect of C26 cancer cachexia on food intake (4).  Approval was obtained by the Institutional Animal Care and 116 
Use Committee (#A16-39) before any procedures were performed.  Body and organ weights, muscle fiber size, 117 
and mitochondrial respiration data from this cohort of C26 mice were reported previously (18) and were used 118 
here to establish relationships with proteomic analyses generated by liquid chromatography-tandem mass 119 
spectrometry (LC-MS/MS) and immunoblotting.   120 
 121 
C26 tumor cell culture and injection  122 
C26 cells were cultured in a humidified incubator with 5% CO2 using media that contained RPMI 1640 123 
with 1% penicillin/streptomycin (vol/vol) and 10% FBS (vol/vol) (CLS Cell Lines Service, Eppelheim, Germany).  124 
Culture media was replaced every two to three days.  At sub-confluency, cells were harvested by incubation 125 
with trypsin (0.05%, Gibco) and pelleted by centrifugation.  The supernatant was discarded and the pellet 126 
resuspended in sterile PBS.  Viable cells were identified and counted in a hemocytometer by trypan blue 127 
staining and light microscopy.  Mice assigned to C26 groups were injected subcutaneously in the upper back 128 
with a cell suspension containing 1 x 106 cells.  Mice assigned to the control group were administered an 129 
equivalent volume of sterile PBS (8, 21). 130 
 131 
Tissue collection  132 
Mice were euthanized by overdose with ketamine/xylazine cocktail injected i.p. (300/30 mg/kg).  133 
Euthanasia was performed during a four-hour time window from 10:00 am to 2:00 pm to ensure consistency in 134 
the timing of tissue collection.  In order to attain 10% and 20% weight loss in moderate and severe cachexia, 135 
respectively, body weight was routinely monitored following tumor cell injection.  Based upon our previous 136 
experience, we expected a final tumor mass at necropsy of ~2g with severe cachexia (20% target weight loss), 137 
and a tumor mass of ~1g with moderate cachexia (10% target weight loss).  These parameters were factored 138 
into routine weight monitoring because measurements of body weight made before euthanasia would be 139 
confounded by tumor weight.  For the typical Balb/c adult male weighing 25g, a tumor mass of 1g would 140 
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represent ~3-4% of body weight.  During routine monitoring, a mouse showing ~7% weight loss would be 141 
euthanized in anticipation of tumor mass accounting for ~3-4% of body weight.  This enabled the target weight 142 
loss of 10% for the moderate cachexia group (C26-MOD), with tissue being collected on day 14 (n=4), 15 143 
(n=1), 17 (n=1), and 21 (n=1).  For mice with confirmed, palpable tumors but no weight loss (C26-WS), tissue 144 
was collected on day 14 (n=1), 20 (n=2), and 21 (n=3).  For all mice with severe cachexia (C26-SEV, n=6), 145 
tissue was collected on day 21 post-injection.  Mice were not food deprived overnight or immediately prior to 146 
tissue collection.  Collected tissue samples were weighed, sectioned, snap frozen and stored at -80°C.   147 
 148 
High-resolution respirometry 149 
Mitochondrial respiration was measured in situ in fresh liver tissue as we previously described and 150 
reported (18).  Briefly, duplicate sections of liver tissue weighing ~6 mg each were gently separated in BIOPS 151 
solution under a dissecting microscope.  Mechanically separated samples were placed into the respirometer 152 
chambers (Oxygraph-2k, Oroboros Instruments) and analyzed by injection of substrates, uncouplers, and 153 
inhibitors to determine mass-specific oxygen flux (pmol·s-1·mg-1).  Several indicators of mitochondrial coupling 154 
were derived from high-resolution respirometry experiments including the respiratory control ratio (RCR), an 155 
index of OXPHOS coupling efficiency, which was calculated by dividing complex I supported OXPHOS by 156 
complex I supported LEAK respiration.  In addition, LEAK respiration was normalized to both maximal 157 
OXPHOS and electron transfer system (ETS) capacities, which were obtained from injection of complex I and 158 
II linked substrates and 5 mM ADP (OXPHOS) or 0.5 µM CCCP (ETS).      159 
 160 
Sample preparation and TMT labeling    161 
Harvested liver tissue was transferred to lysis buffer (8 M Urea, 1 mM phenylmethylsulfonyl fluoride, 1x 162 
protease inhibitor cocktail) and sonicated (SONICS VCX750; amplitude 35%; pulse on 1 sec; pulse off 3 sec; 163 
total processing time 3 min) to release cell contents.  Protein quantitation was performed  using the Pierce 164 
quantitative colorimetric assay kit at λ = 480 nm according to the manufacturer’s instructions (cat# 23275, 165 
ThermoFisher Scientific, USA).  250 ug of total protein per sample were then reduced with 200 mM tris(2-166 
carboxyethyl)phosphine at 56°C for 1 h followed by alkylation with 20 mM iodoacetamide at room temperature 167 
in the dark for 1 h.  An equal amount of protein was used for each tryptic digestion (1:50 ratio of 168 
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trypsin:substrate) at 37 °C overnight after which time the reaction was quenched with 0.1% formic acid.  169 
Samples were then lyophilized and subsequently dissolved in 100 mM triethylammonium bicarbonate.  Tryptic 170 
peptides, 50 ug per sample, were labeled with TMT reagents for 1 h at room temperature after which the 171 
reaction was quenched with 5% hydroxylamine.  Samples from each group were combined with equal amounts 172 
of TMT labeled internal standard, which was comprised of a mixture of protein extracts from all 23 samples.  173 
The sample labeling scheme is shown in Supplementary Table S1.  Each pooled sample was then fractionated 174 
using RP-HPLC (Waters 2695 HPLC System equipped with Thermo Betasil C18 column, 80Å, 10 mm x 250 175 
mm, 5 μm) with the separation gradient set to 8-32% B in 60 min (flow rate = 1mL/min, 20°C; A: 0.1% formic 176 
acid in water; B: 0.1% formic acid in acetonitrile) to yield 6 fractions. 177 
 178 
LC-MS/MS and data analysis 179 
Fractionated peptides were further separated using Nanoflow UPLC: Ultimate 3000 nano UHPLC 180 
system (ThermoFisher Scientific, USA) equipped with a trapping column (PepMap C18, 100 Å, 110 μm x 2 cm, 181 
5μm) and an analytical column (PepMap C18, 100 Å, 75 μm x 50 cm, 2 μm).  LC linear gradient was set to 2-182 
8% B in 3 min, 8 to 20% B in 50 min, 20-40% B in 26 min, and 40-90% B in 4 min (A: 0.1% formic acid in 183 
water; B: 0.1% formic acid in 80% acetonitrile) with flow rate = 250 nL/min at 20°C.  Peptides were then 184 
analyzed with Q Exactive HF mass spectrometer (ThermoFisher Scientific, USA).  Precursor ion range was set 185 
to 300.0-1650.0 with 6x104 resolution at 200 m/z and MS/MS product range starting from 100 m/z.  Data was 186 
acquired in data dependent acquisition mode with up to 20 most intense peptide ions from preview scan 187 
selected for MS/MS.  From each group 6 raw MS files were searched against mouse protein database using 188 
Maxquant (1.5.6.5).  Search parameters included carbamidomethylation of cysteine (fixed) and oxidation of 189 
methionine (variable) in protein modification; enzyme specificity was set to trypsin with maximum of 2 missed 190 
cleavages and mass tolerance of 10 ppm for precursor ion and 0.6 Da for MS/MS.  Proteins were selected for 191 
further analysis based on ≥1 unique peptides identified.  The false discovery rate (FDR) was set to <1%. 192 
 193 
Tissue homogenate  194 
For all other in vitro experiments, liver tissue homogenate was prepared as we recently described (18). 195 
Briefly, 250 mg liver tissue was excised and washed with ice-cold mitochondrial isolation buffer 196 
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(215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 1 mM EGTA, and pH adjusted to 7.2 with 197 
KOH).  Subsequently, tissue was homogenized in 1 mL of mitochondrial isolation buffer using a manual Potter-198 
Elvehjem tissue grinder.  The tissue homogenate was frozen immediately at -80 °C for later biochemical 199 
assays and western blotting.  Protein concentration was determined by BCA kit (Pierce, Rockford, Il, USA).  200 
 201 
Biochemical assays 202 
Hepatic galactose (cat# ab83382, Abcam), free fatty acid (cat# ab65341, Abcam), triglyceride (cat# 203 
ab65336, Abcam) and glycogen (cat# K646, Biovision) content, as well as α-glucosidase (cat# ab174093, 204 
Abcam) and acyl-CoA synthetase (cat# K184, Biovision) enzyme activity was assayed using commercially 205 
available kits according to the manufacturers’ protocols.  The α-glucosidase enzyme activity was measured 206 
spectrophotometrically at λ = 410 nm.  For the remaining assays, fluorescence signals generated from 207 
samples were measured at λexcitation = 530 nm and λemission = 590 nm filters by a Biotek Synergy HTX 208 
spectrofluorometer (Winooski, VT).  All parameters were normalized against total protein concentrations. 209 
 210 
Western blotting    211 
For western blot analysis, 30 μg of protein homogenate was mixed with 4X Laemmli sample buffer 212 
(cat# 161-0747, Bio-Rad) containing 355 mM 2-mercaptoethanol and separated on SDS-polyacrylamide gel 213 
electrophoresis, using 4–20% Criterion™ TGX™ Precast gels (cat# 5671095, Bio-Rad).  The gel proteins were 214 
transferred onto an Immun-Blot PVDF membrane and then blocked with 5% nonfat dry milk in TBST buffer 215 
(Tris-buffered saline, 0.1% Tween-20) for 1 hour at room temperature.  The PVDF membrane was incubated 216 
with the following primary antibodies overnight on a shaker at 4 °C in 5% milk: mitochondrial OXPHOS 217 
complexes (I to V) mouse mAb cocktail (1:2000, cat#ab110413, Abcam), 4-hydroxynonenal rabbit polyAb (4-218 
HNE, 1:1000 dilution, cat# ab46545, Abcam), long-chain acyl-CoA synthetase 1 (ACSL1, 1:2000 dilution, cat# 219 
4047, Cell Signaling) and GAPDH rabbit mAb (1:5000 dilution, cat# 5174, Cell Signaling).  GAPDH was taken 220 
as an internal protein loading control.  After 3 times TBST wash, the membranes were incubated with 221 
appropriate horseradish peroxidase (HRP)-conjugated horse anti-mouse IgG (cat#7076, Cell Signaling) or goat 222 
anti-rabbit IgG (cat# 7074, Cell Signaling) secondary antibodies for an hour at room temperature.  Further, 223 
membranes were washed 3 times in TBST and then incubated for 5 minutes in SuperSignal™ West Pico 224 
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PLUS Chemiluminescent Substrate solution (cat# PI34580, Thermo Fisher) for immunoreactive protein 225 
reaction. Subsequently, ChemiDocTM XRS+ imager with Image Lab™ software (Bio-rad) detected the reactive 226 
bands and ImageJ software (NIH) measured individual protein band density. 227 
 228 
Bioinformatics and statistical analysis 229 
Proteins differentially expressed between two compared groups (p-value < 0.05) and with 1.5 or 1/1.5 230 
fold change were deemed significant.  Venn diagrams were generated from protein lists using software by 231 
Ghent University Bioinformatics and Systems Biology (http://bioinformatics.psb.ugent.be/webtools/Venn/).  232 
Heat maps were prepared using Morpheus (https://software.broadinstitute.org/morpheus).  Bioinformatics 233 
analysis of proteomics datasets were performed using STRING version 11 (30), including enrichments of 234 
KEGG and Reactome pathways and UniProt keywords.  Significantly enriched pathways and keywords were 235 
identified by a FDR q-value < 0.05.  Pairwise comparisons for C26-WS vs. C26-MOD, C26-WS vs. C26-SEV, 236 
and C26-MOD vs. C26-SEV were prioritized for bioinformatics.  For each pairwise comparison, differentially 237 
expressed proteins that increased (up-regulated) and decreased (down-regulated) were analyzed separately in 238 
the STRING database (20, 24).  Hepatic glycogen, galactose, free fatty acids, triglycerides, enzyme activity, 239 
and protein expression from immunoblotting experiments were analyzed by one-way ANOVA.  In the event of a 240 
significant F-test, posthoc analysis was conducted using Tukey’s HSD.  Significance was accepted at p<0.05. 241 
 242 
Results 243 
Phenotype of mice with moderate and severe colon-26 cancer cachexia 244 
Tumor mass increased with cachexia severity (Table 1).  Mean body weight loss was 10±1% and 245 
22±2% in C26-MOD and C26-SEV, respectively (Table 1).  Hindlimb muscle mass was ~20-30% lower in C26-246 
MOD and C26-SEV compared to the WS groups (Table 1).  Consistent with whole muscle atrophy, mean fiber 247 
area of the gastrocnemius was ~45-55% lower in C26-MOD and C26-SEV compared to WS groups (Table 1).  248 
Epididymal fat mass was lower in C26-MOD relative to PBS-WS and C26-WS (Table 1).  Epididymal fat was 249 
fully depleted in C26-SEV and not measured (Table 1).  The spleen was enlarged in all C26 groups by ~35-250 
75% compared to PBS-WS (Table 1), indicating an inflammatory response to the C26 tumor.  The liver was 251 
atrophied in C26-MOD and C26-SEV compared to the WS groups (Table 1).  252 
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The liver proteome in colon-26 tumor-induced cachexia 253 
 A total of 2,510 proteins were identified in liver protein extracts by LC-MS/MS, with ~50% common to all 254 
four groups, 3% exclusive to moderate cachexia, 8% unique to severe cachexia, and ~4% common to both 255 
moderate and severe cachexia (Fig. 1a, Table S2).  When using PBS-WS mice as the control, 487 proteins 256 
were differentially expressed in C26-WS (up-/down-regulated: 283/204), 532 in C26-MOD (247/285), and 523 257 
in C26-SEV (250/273) (Fig. 1b, Table S3).  When using C26-WS (cancer non-cachexia) as the control, 771 258 
proteins were differentially expressed in C26-MOD (up-/down-regulated: 355/416), and 769 in C26-SEV 259 
(341/428) (Fig. 1b,c, Table S4).  Thus, selection of control impacts the detection of differentially expressed 260 
proteins in C26 cancer cachexia.  When compared to C26-MOD, 557 proteins were differentially expressed in 261 
C26-SEV (up-/down-regulated: 260/297) (Fig. 1b,d, Table S4), and these proteins may be involved in the 262 
transition from moderate to severe cachexia.   263 
A Venn diagram generated from the differentially expressed proteins in C26-WS vs. C26-MOD, and 264 
C26-MOD vs. C26-SEV, revealed an overlap region of 306 proteins (Fig. 1e, Table S5).  These 306 proteins 265 
are differentially regulated at the induction of moderate cachexia, and in the transition to severe cachexia.  266 
Thus, these proteins may represent a hepatic proteomic signature needed to maintain the cachexic state.  267 
Functional annotation by KEGG pathways enrichment showed metabolic pathways, Alzheimer’s disease, 268 
Parkinson’s disease, Huntington’s disease, lysosome, oxidative phosphorylation, and non-alcoholic fatty liver 269 
disease among the top 10 pathways (Fig. 1e).  Dysregulation of mitochondrial function, particularly in its 270 
metabolic activities such as OXPHOS, are common to Alzheimer’s, Huntington’s, Parkinson’s, and non-271 
alcoholic fatty liver diseases, suggesting altered liver mitochondrial OXPHOS to also feature in cachexia 272 
regardless of severity.  Further, 251 differentially expressed proteins were unique only in severe cachexia (Fig. 273 
1e and Table S5), and these proteins (of the total 557 differentially expressed in severe vs. moderate) may be 274 
influential in supporting the transition from moderate to a severe presentation of the disease.  275 
 276 
Altered mitochondrial function and substrate metabolism in moderate cachexia 277 
 Differentially expressed proteins were analyzed separately in STRING.  KEGG pathways enrichment of 278 
proteins down-regulated in moderate cachexia included metabolic pathways, Alzheimer’s disease, 279 
Huntington’s disease, Parkinson’s disease, oxidative phosphorylation, thermogenesis, and non-alcoholic fatty 280 
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liver disease among the top 10 pathways (Fig. 2a).  These enriched pathways suggest a depression in liver 281 
mitochondrial OXPHOS to be associated with early cachexia.  In addition, ~20% of genes involved in the TCA 282 
cycle were identified (relative to background gene count) in the down-regulated list, the largest among the 283 
represented pathways (Fig. 2a).  Similarly, UniProt keywords enrichment analysis lists ‘mitochondrion’, 284 
‘mitochondrion inner membrane’, ‘oxidoreductase’, ‘respiratory chain’, and ‘electron transport’ in the top 15 285 
represented keywords from the down-regulated protein list (Table S6).  The reactome pathways enrichment 286 
analysis also identified terms related to energy metabolism and mitochondrial function among the top 10 287 
pathways (Table S6).   288 
KEGG pathways enrichment of the up-regulated protein list in moderate cachexia show metabolic 289 
pathways, complement and coagulation cascades, carbon metabolism, biosynthesis of amino acids, protein 290 
processing in the endoplasmic reticulum, proteasome, amino sugar and nucleotide sugar metabolism, 291 
lysosome, and glycolysis/gluconeogenesis among the top 10 represented pathways (Fig. 2a).  Galactose 292 
metabolism equated to ~20% of the observed/background gene count (Fig. 2a).  Thus, metabolism of 293 
carbohydrates, proteins/amino acids, and nucleic acids are prominent in the livers of moderately cachexic 294 
mice.  ‘Mitochondrion’, ‘oxidoreductase’, and ‘electron transport’ are represented in the top 20 keywords, 295 
indicating that some proteins associated with mitochondrial metabolism are increased (Table S6).  ‘Acute 296 
phase’ appears as a top 10 keyword from the up-regulated protein data set (Table S5), consistent with the 297 
complement and coagulation cascades in the KEGG analysis.  After ‘thioester bond’, ‘acute phase’ is the most 298 
represented enrichment by percentage in the up-regulated protein list with an observed/background gene 299 
count of ~30% (Table S6).  The reactome pathways further supports a role of the acute phase response in 300 
moderate cachexia, with innate immune system and immune system in the top 5 (Table S6).   301 
 302 
Transition to severe cachexia is also associated with altered energy metabolism 303 
 KEGG analysis of down-regulated proteins in severe cachexia showed metabolic pathways, 304 
proteasome, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, oxidative phosphorylation, non-305 
alcoholic fatty liver disease, lysosome, drug metabolism, and thermogenesis among the top 10 enriched 306 
pathways (Figs. 2b, 3a), pointing to a suppression of mitochondrial OXPHOS similar to moderate cachexia.  307 
This suppression is consistent with the UniProt analysis where ‘respiratory chain’, ‘mitochondrion’ and ‘electron 308 
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transport’ appear in the top 20 keywords (Table S7), and with the immunoblots of selected respiratory chain 309 
subunits (Fig. 3b).  The proteasome accounted for the greatest percentage of genes represented in the KEGG 310 
analysis at ~30% observed relative to the background gene count (Fig. 2b).  This aligns with the UniProt 311 
keywords analysis which indicated ‘proteasome’ to be the third ranked pathway by FDR, and second most 312 
observed/background gene count at 25% (Table S7).  In the transition to severe cachexia, galactose 313 
metabolism was enriched in the down-regulated protein list, with a 16% observed/background gene count.  314 
This was the third highest percentage among all enriched pathways (Fig. 2b).  Other glycan degradation was 315 
also an enriched KEGG pathway with observed/background gene count of 12% (Fig. 2b), supportive of 316 
ongoing carbohydrate metabolism in severe cachexia.   317 
 KEGG analysis of the up-regulated proteins yielded only 12 enriched pathways, with metabolic 318 
pathways, RNA transport, spliceosome, ribosome, and peroxisome represented in the top 5 (Fig. 2b).  The 319 
UniProt keywords enrichment lists ‘ribonucleoprotein’, ‘RNA binding’, ‘mRNA splicing’, ‘mRNA processing’, 320 
‘ribosomal protein’, ‘spliceosome’, and ‘initiation factor’ all represented in the top 20 (Table S7).  Reactome 321 
pathways also showed predominant representation by translation and related events (Table S7).  Together this 322 
points to increased processing of mRNA and protein synthesis.  As in moderate cachexia, ‘acute phase’ 323 
remains an enriched keyword in severe cachexia (Table S8), implying an acute phase inflammatory response 324 
that persists across cachexia severity. 325 
 326 
Hepatic carbohydrate metabolism in colon-26 tumor-induced cachexia 327 
 Bioinformatics revealed galactose metabolism to be significantly enriched in moderate cachexia, and in 328 
the transition to severe cachexia (Fig. 2a,b).  Galk1, Galt, and Gale, three major proteins of the Leloir pathway 329 
responsible for interconversion of galactose and glucose, were increased in moderate cachexia and decreased 330 
from moderate to severe cachexia (Fig 4a).  Their abundance, however, remained elevated in the severe state 331 
relative to non-cachexic controls (C26-WS) (Fig. 4a), suggesting that enzymes regulating galactose 332 
metabolism in moderate cachexia tends to persist into the severe state.  Enrichment of these enzymes could 333 
allow for the catabolism of galactose and subsequent entry into the glycolytic pathway.  Interestingly, galactose 334 
content in liver homogenates was not affected by cachexia (Fig. 4b) despite the increased expression of 335 
several key enzymes.  Lysosomal α-glucosidase, which regulates glycogen catabolism in lysosomes, showed 336 
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especially robust increase based on fold-change (>7 vs. C26-WS) without altered activity (Figs. 4a,c).  337 
Consistent with glycogen breakdown, glycogen content in liver tissue homogenates are in fact decreased in 338 
cachexia (Fig. 4d), implying active glycogenolysis.  Presumptive conversion of glycogen into glucose 1-339 
phoshate and glucose 6-phosphate would suggest increased activity of glycogenolysis and glycolysis.  Indeed, 340 
glycolysis is represented in the KEGG analysis of up-regulated proteins (Fig. 2a). 341 
 Given the impairment of mitochondrial OXPHOS and catabolism of carbohydrates, as well as previous 342 
suggestions of altered lactate metabolism in cancer cachexia, we explored the proteomics data sets for 343 
differentially expressed proteins involved in lactate metabolism and transport.  We found decreased pyruvate 344 
dehydrogenase protein X component (Pdhx) and increased abundance of lactate dehydrogenase A chain 345 
(Ldha) according to LC-MS/MS (Table S4, Fig. 4e), changes which are expected to favor lactate formation.  346 
We also found that the lactate transporter monocarboxylate transporter 1 (Mct1) was expressed in livers of 347 
mice with both moderate and severe cachexia (Table S2, Fig. 4e).  Mct1 was increased in C26-SEV compared 348 
to C26-MOD (fold-change 2.62, P<0.05) (Table S4), suggesting that Mct1 expression increases with cachexia 349 
severity.  Collectively, these data indicate greater abundance of proteins that favor lactate formation as well as 350 
a key lactate transporter that could facilitate futile cycling of lactate between the livers of cachexic mice and the 351 
tumor. 352 
 353 
Hepatic lipid metabolism in colon-26 tumor-induced cachexia 354 
 Previous reports of abnormal lipid metabolism in cancer cachexia agreed with our bioinformatics 355 
analysis, which showed enrichment of fatty acid metabolism (Fig. 3a, Table S8).  We therefore further 356 
examined how fatty acid transport and oxidation were affected by cachexia.  No differences were detected by 357 
LC/MS-MS in members of the fatty acid transport protein (FATP) family or fatty acid translocase/CD36 (Table 358 
S4), suggesting that fatty acid transport across the hepatic cell membrane was not affected by cachexia.  No 359 
differences were detected in carnitine palmitoyltransferase I (Cpt1a) (Table S4), which is responsible for fatty 360 
acid transport across the mitochondrial outer membrane.  There was a decrease, however, in 361 
carnitine/acylcarnitine carrier protein (Table S4), which regulates fatty acid transport across the inner 362 
membrane into the matrix.  Together this suggests a possible impairment of fatty acid transport into the 363 
mitochondrial matrix.   364 
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We next generated a heatmap showing the abundance of proteins associated with fatty acid oxidation 365 
in C26 livers (Fig. 5a).  Of these proteins, 20 were differentially expressed in moderate and/or severe cachexia 366 
(Fig. 5a).  These differentially expressed proteins showed significant relationships with hallmark features of 367 
cancer cachexia including body weight change and muscle fiber size (Fig. 5b).  They also showed significant 368 
relationships with indices of mitochondrial coupling including the respiratory control ratio, an index of OXPHOS 369 
coupling efficiency, and LEAK respiration (surrogate of proton leak) normalized to maximal OXPHOS and 370 
electron transfer system (ETS) capacities (Fig. 5b).  Among the 20 differentially expressed proteins, 6 were 371 
decreased in both moderate and severe cachexia (Fig. 5a).  These 6 proteins included alcohol dehydrogenase 372 
1 (Adh1), 3-ketoacyl-CoA thiolases A (Acaa1a) and B (Acaa1b), peroxisomal L-bifunctional enzyme (Ehhadh), 373 
long chain enoyl-CoA hydratase/long-chain 3-hydroxyacyl-CoA dehydrogenase (Hadha), and long chain acyl-374 
CoA synthetase 1 (ACSL1).  With the exception of Adh1, these proteins are essential components of 375 
peroxisomal and mitochondrial beta-oxidation (Figs. 5c,d).  Collectively, this profile suggests dysregulation of 376 
the beta-oxidation machinery and an impaired ability of the cachexic liver to oxidize lipids. 377 
An impairment of hepatic lipid oxidation would be expected to cause an accumulation of lipids in the 378 
liver, which in turn may contribute to uncoupling of OXPHOS.  To confirm the presence of hepatic steatosis, we 379 
assayed free fatty acids and triglycerides in liver tissue homogenates.  Both were decreased in severe 380 
cachexia (Fig. 5e,f), and these events were preceded by increased acyl-CoA synthetase enzyme activity (Fig. 381 
5g).  Together this implies that lipid oxidation remains intact in the cachexic liver and that lipid accumulation 382 
and lipotoxicity is not a significant contributor to uncoupling of OXPHOS.  To explore the possibility that 383 
oxidative stress to lipids contributes to uncoupling of OXPHOS in the cachexic liver, we assayed 4-HNE 384 
formation in liver tissue homogenates by immunoblotting (Fig. 6).  4-HNE formation from 15-250 kDa in the full 385 
blot was not different between groups (P>0.05) (Fig. 6b).  However, there was significantly greater 4-HNE 386 
formation in the ~37-45 kDa bands in severe cachexia compared to non-cachexic control (Fig. 6c), suggesting 387 
the presence of some lipid peroxidation and cellular oxidative damage.  Therefore, tumor-induced oxidative 388 
stress may contribute to uncoupling of OXPHOS in the cachexic liver. 389 
 390 
Loss of acyl-CoA synthetase-1 (ACSL1) in colon-26 tumor-induced cachexia 391 
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ACSL1 is a key fatty acyl-CoA synthetase responsible for activating imported long-chain fatty acids by 392 
esterification with coenzyme A, thereby enabling further processing (e.g. by oxidation).  Our proteomics 393 
analysis indicated decreased hepatic ACSL1 in moderate and severe cachexia (Fig. 5a).  To validate this 394 
finding, we probed for ACSL1 in liver tissue homogenates by follow-up immunoblotting experiments.  Indeed, 395 
ACSL1 expression showed a clear stepwise decrease as cachexia worsened (Figs. 7a,b).  ACSL1 had strong 396 
linear relationships with percent body weight change (r=0.874, P<0.01) and myofiber size (r=0.856, P<0.01), 397 
the hallmark features of cancer cachexia (Fig. 7c).  These correlations suggest greater hepatic ACSL1 in 398 
weight-stable mice with larger muscles, and lower ACSL1 in weight-losing mice with smaller muscles.  ACSL1 399 
also related linearly with the respiratory control ratio (r=0.618, P<0.01), an index of OXPHOS coupling 400 
efficiency, and inversely with LEAK respiration normalized to maximal electron transfer system capacity (r=-401 
0.505, P<0.05) (Fig. 7c).  Together these correlations suggest that weight-stable mice with larger myofibers 402 
and higher hepatic Acsl1 also had lower proton leak consistent with tighter OXPHOS coupling and 403 
energetically efficient mitochondria that dissipate less heat.   404 
 405 
Discussion 406 
Mass spectrometry-based proteomics have been used to profile cachexic skeletal muscle, but we are 407 
unaware of its application in cachexic liver.  Here we report proteome wide changes in livers from mice with 408 
moderate and severe cancer cachexia.  Of the roughly 2,500 hepatic proteins detected by mass spectrometry, 409 
20-30% (~600-800) were identified as being differentially expressed in moderate and severe cachexia.  This 410 
high number of differentially expressed proteins highlights the potential role of liver metabolism in cancer 411 
cachexia.  By comparison, in the mdx-4cv mouse model of muscular dystrophy, only ~100 of the roughly 2,000 412 
hepatic proteins detected (~5%) were found to be differentially regulated (24).  The relatively lower proportion 413 
of differentially expressed proteins in muscular dystrophy could be explained by the disease being mainly a 414 
pathology of skeletal muscle, with only indirect effects on the liver.  The greater percentage of hepatic proteins 415 
identified as differentially expressed in our C26 mice implies the liver, in addition to skeletal muscle, to be a 416 
significant contributor to cancer cachexia onset and progression, and an important site for targeted therapies. 417 
To derive biological interpretations of our proteomics datasets centered on cachexia severity, we used 418 
standard bioinformatics software to analyze differentially expressed protein lists sorted by increased and 419 
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decreased abundance.  Bioinformatics revealed mitochondrial OXPHOS, TCA cycle, and/or thermogenesis to 420 
be represented during the induction of moderate cachexia (Figs. 2, Tables S2-3), and in the transition to 421 
severe disease (Figs. 3, Tables S4-5), suggesting a role for hepatic mitochondrial function in the onset and 422 
progression of cancer cachexia.  We previously reported loss of in situ OXPHOS capacity in livers from the 423 
same cohort of cachexic C26 mice (18), in line with OXPHOS being represented in down-regulated protein lists 424 
(Figs. 2-3).  Interestingly, thermogenesis was also represented in down-regulated protein lists in moderate 425 
cachexia (Figs. 2a, Table S2), and in the transition to severe cachexia (Fig. 3a).  If cachexic livers dissipate 426 
energy and produce heat from mitochondrial uncoupling, an increase rather than a decrease in thermogenic 427 
pathways might be expected.  In phenotyping experiments, cachexic liver mitochondria show reduced P:O (i.e. 428 
lower ATP produced per molecule of oxygen consumed) (9), which suggests compromised coupling efficiency 429 
and energy wasting.  Further, we previously observed loss of coupling control in livers from the same cohort of 430 
cachexic C26 mice in this study, reflecting inefficiency of OXPHOS due in part to increased LEAK respiration 431 
and Ant2, an inner membrane protein with uncoupling function (18).  The current investigation also provided 432 
evidence of oxidative stress as reflected by greater 4-HNE formation (Fig. 6), which may lead to uncoupling as 433 
an ameliorative response.  Together this data implies uncoupling of liver mitochondria in cachexic mice.  It is 434 
possible that the enrichment of thermogenesis in down-regulated datasets reflects a compensatory effort to 435 
minimize uncoupling. 436 
A noteworthy finding in the proteomics analysis was the identification of differentially expressed 437 
proteins in cachexic livers that would impact lactate metabolism and transport.  Cachexic livers displayed 438 
decreased pyruvate dehydrogenase protein X component (Pdhx), increased lactate dehydrogenase A chain 439 
(Ldha), and increased lactate transporter Mct1 (Table S4, Fig. 4).  Given that these cachexic C26 livers also 440 
demonstrated catabolism of glycogen and impaired OXPHOS, increased lactate formation and transport 441 
involving extrahepatic tissues might be an anticipated outcome.  Such inter-organ lactate cycling has been 442 
previously proposed and discussed by many in recent frameworks defining potential mechanisms of cancer 443 
cachexia (1-3, 12, 13, 25, 32).  Often described is a Cori cycle in which significant use of glucose by the tumor 444 
generates lactate, which is then exported and shuttled to the liver.  Imported lactate is then used by the liver as 445 
a gluconeogenic substrate, which further supplies glucose to the tumor.  This cycling of lactate is associated 446 
with energetic inefficiency because metabolism of glucose into lactate by the tumor generates less ATP (i.e. 2) 447 
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compared to the energy cost to convert lactate into glucose (i.e. 6 ATP) within the liver.  Thus, while the 448 
premise of altered lactate metabolism involving the liver and tumor has been previously suggested, we are 449 
unaware of extensive experimental data to support these assertions specifically in cancer cachexia.  Further 450 
clarification would strengthen the existence of energetically inefficient inter-organ transport between the liver 451 
and tumor, such as blood lactate concentration, the expression Mct1 and related family members as well as 452 
glucose, pyruvate, and lactate content in both the liver and cachexia inducing C26 tumors. 453 
A novel finding in the present work was the loss of ACSL1 in cachexic livers, which to our knowledge 454 
has not been previously reported.  As cachexia worsened, ACSL1 decreased in tandem.  This outcome was 455 
observed in both LC-MS/MS and immunoblotting experiments (Figs. 5,7).  ACSL1 is well-known for activating 456 
long chain fatty acids to form acyl-CoAs prior to further processing (e.g. oxidation) (22).  ACSL1 has also been 457 
shown to positively influence mitochondrial function and coupling in several cell and disease models.  In mice 458 
with heart failure, cardiac-specific overexpression of ACSL1 maintained mitochondrial oxidative energy 459 
metabolism (16).  Further, overexpression of ACSL1 in Schwann cells reduced oxidative stress, normalized 460 
mitochondrial function, improved mitochondrial coupling efficiency, and reduced proton leak across the inner 461 
membrane (19).  These findings have intriguing implications for cancer cachexia.  Cachexic C26 livers showed 462 
evidence of oxidative stress as indicated by 4-HNE formation (Fig. 6).  Further, cachexic C26 liver exhibits 463 
uncoupling due in part to reduced OXPHOS and increased LEAK respiration (18).  Uncoupling of OXPHOS 464 
may contribute to cachexia-associated weight loss by dissipation of energy as heat and increase in whole body 465 
energy expenditure (Fig. 7d).  The possibility exists that targeted overexpression of ACSL1 in the cachexic liver 466 
may be sufficient to improve mitochondrial function and coupling by increasing OXPHOS and/or reducing 467 
proton leak, thereby mitigating heat production and normalizing energy expenditure.  ACSL1 may therefore be 468 
a candidate hepatic target for therapeutic intervention.   Follow-up experiments in which ACSL1 is directly 469 
manipulated in vivo are warranted to better understand whether ACSL1 has the potential to slow cancer 470 
cachexia. 471 
We note that food records for this investigation were incomplete, therefore we were unable to provide 472 
food intake data for this cohort of mice.  This information is important to understand whether reduced energy 473 
intake may have contributed to cachexia-associated body weight loss, muscle atrophy, and changes to the 474 
hepatic proteome.  In a previous investigation that used C26 cells from the same cell bank, food intake in 475 
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cachexic C26 mice was not different from controls (4).  This finding raises the possibility that our C26 mice 476 
would also not exhibit significant anorexia, although this remains to be verified.   477 
We conclude that the liver is an important site for targeted therapeutic strategies in cancer cachexia.  478 
Altered hepatic mitochondrial function is a common feature of both moderate and severe cancer cachexia.  479 
Proteome profiling suggests altered lactate metabolism and transport in cachexic livers, which raises the 480 
possibility of energetically inefficient lactate shuttling between the liver and tumor that elevates whole body 481 
energy expenditure and causes weight loss.  Tumor-induced oxidative damage may contribute to uncoupling of 482 
cachexic liver mitochondria, which could also increase energy expenditure and weight loss.  As cancer 483 
cachexia severity worsens, ACSL1 levels in the liver decline.  In mice with the highest levels of ACSL1, body 484 
weight was greater, muscles were larger, and mitochondria better coupled.  We propose that ACSL1 is a 485 
candidate target to consider for future experiments that aim to unravel mechanisms and therapies for cancer 486 
cachexia.   487 
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Figure Legends 624 
Figure 1.  Moderate and severe cancer cachexia share ~300 differentially expressed proteins in liver 625 
(a) Venn diagram illustrating the total number of proteins identified in each group, and the number of shared 626 
proteins between groups.  A total of 2,510 proteins were identified by liquid chromatography-tandem mass 627 
spectrometry.  Livers were assayed from PBS Weight-Stable (PBS-WS, n=4), C26 Weight-Stable (C26-WS, 628 
n=6), C26 Moderate (C26-MOD, n=7), and C26 Severe (C26-SEV, n=6).  (b) Number of differentially 629 
expressed proteins that are up- or down-regulated for each paired comparison.  (c-d) Heat maps generated 630 
from differentially expressed proteins during the induction of moderate cachexia (C26-WS vs. C26-MOD), and 631 
the transition from moderate to severe presentation of the disease (C26-MOD vs. C26-SEV).  (e) Venn 632 
diagram generated by using differentially expressed proteins detected during the induction of moderate 633 
cachexia (C26-WS vs. C26-MOD), and the transition from moderate to severe presentation of the disease 634 
(C26-MOD vs. C26-SEV).  The 306 shared proteins in the overlap region may be necessary to maintain the 635 
cachexic state, and are hypothesized to represent a proteomic signature of cachexia.  KEGG pathways 636 
enrichment of these differentially expressed proteins was conducted with STRING.  The top 15 KEGG 637 
pathways are shown.   638 
 639 
Figure 2.  KEGG pathways enrichment of differentially expressed proteins in moderate cachexia 640 
(a) KEGG pathways enrichment of down-regulated and up-regulated protein datasets in moderate cachexia.  641 
Enriched KEGG pathways were identified from differentially expressed hepatic proteins in C26 Moderate 642 
cachexia (C26-MOD, n=7) relative to C26 Weight-Stable (C26-WS, n=6) using the STRING database.   (b) 643 
KEGG pathways enrichment of down-regulated and up-regulated protein datasets in the transition from 644 
moderate to severe cachexia.  Enriched KEGG pathways were identified from differentially expressed hepatic 645 
proteins in C26 Severe (C26-SEV, n=6) relative to C26 Moderate (C26-MOD, n=7) using the STRING 646 
database.  Values adjacent to individual bars are the percentage of identified genes from the imported protein 647 
list relative to the background gene count for that pathway, and the false discovery rate q-value. 648 
 649 
 650 
 651 
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Figure 3.  KEGG pathways enrichment of differentially expressed proteins in severe cachexia 652 
(a) KEGG pathways enrichment of down-regulated and up-regulated protein datasets in severe cachexia.  653 
Enriched pathways were identified from differentially expressed hepatic proteins in C26 mice with severe 654 
cachexia (C26-SEV, n=6) relative to C26 Weight-Stable (C26-WS, n=6) using the STRING database.  Values 655 
adjacent to individual bars are the percentage of identified genes from the imported protein list relative to the 656 
background gene count for that pathway, and the false discovery rate q-value.  (b) Top panel is showing 657 
immunoblots for complex I-V subunits of the mitochondrial respiratory chain probed in liver tissue 658 
homogenates.  Bottom figure is showing expression of the complex I-V subunits normalized to GAPDH.  Data 659 
presented as mean ± SE.  Tissues assayed from PBS Weight-Stable (n=4), C26 Weight-Stable (n=6), C26 660 
Moderate (n=7), and C26 Severe (n=6).  Differences determined by one-way ANOVA.  p<0.05 (*), p<0.01 (**), 661 
p<0.001 (***). 662 
 663 
Figure 4.  Hepatic carbohydrate metabolism in colon-26 tumor-induced cachexia. 664 
(a) Fold-changes for differentially expressed proteins involved in galactose metabolism.  Arrows represent 665 
increased or decreased abundance and values indicate the magnitude of the fold-change.  Shown are proteins 666 
that were differentially expressed in moderate cachexia (C26-WS vs. C26-MOD), severe cachexia (C26-WS 667 
vs. C26-SEV), or the transition from moderate to severe cachexia (C26-MOD vs. C26-SEV). (b-d) Galactose, 668 
α-glucosidase enzyme activity, and glycogen content in liver homogenates were measured by fluorometry and 669 
spectrophotometry.  Tissues assayed from C26 Weight-Stable (n=6), C26 Moderate (n=7), and C26 Severe 670 
(n=6).  Differences determined by one-way ANOVA.  p<0.05 (*).  (e) Summary of findings involving 671 
carbohydrate metabolism in the cachexic liver.  LC-MS/MS indicated decreased pyruvate dehydrogenase 672 
protein X component (Pdhx), increased lactate dehydrogenase A chain (Ldha), and increased lactate 673 
transporter Mct1.  Cachexic C26 livers also demonstrated catabolism of glycogen and impaired OXPHOS, 674 
therefore increased lactate formation and transport involving extrahepatic tissues (e.g. the tumor) are 675 
expected.  Such inter-organ lactate cycling is associated with energetic inefficiency because metabolism of 676 
glucose into lactate by the tumor generates less ATP (i.e. 2) compared to the energy cost to convert lactate 677 
into glucose (i.e. 6 ATP) within the liver. 678 
 679 
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Figure 5.  Hepatic lipid metabolism in colon-26 tumor-induced cachexia. 680 
(a) Heatmap of hepatic proteins involved in lipid oxidation from C26 weight-stable mice (C26-WS, n=6), C26 681 
mice with moderate cachexia (C26-MOD, n=7), and C26 mice with severe cachexia (C26-SEV, n=6).  (b) Of 682 
the hepatic proteins shown in the heatmap, 20 were differentially expressed in moderate cachexia (C26-WS 683 
vs. C26-MOD), severe cachexia (C26-WS vs. C26-SEV), or the transition from moderate to severe cachexia 684 
(C26-MOD vs. C26-SEV).  These 20 differentially expressed proteins were correlated with hallmark features of 685 
cancer cachexia and indicators of mitochondrial coupling, as shown in the table color-coded by maximum (red) 686 
and minimum (blue) Pearson-r correlation coefficients.  The hallmark features of cachexia were percent body 687 
weight change, and muscle fiber cross-sectional area (CSA) determined by hematoxylin staining and standard 688 
morphometric techniques.  Indicators of mitochondrial coupling were derived from high-resolution respirometry 689 
experiments including the respiratory control ratio (RCR), and LEAK respiration normalized to maximal 690 
oxidative phosphorylation (OXPHOS) and electron transfer system (ETS) capacities.  Weight change, myofiber 691 
size, and respiration data were previously published (18).  p<0.05 (*), p<0.01 (**), p=0.05-0.09 (^) (c-d)  692 
Proteins regulating mitochondrial and peroxisomal beta-oxidation of fatty acids are differentially expressed in 693 
moderate (C26-WS vs. C26-MOD) and severe cachexia (C26-WS vs. C26-SEV).  (e-g) Total free fatty acids, 694 
triglycerides, and acyl-CoA synthetase enzyme activity in liver homogenates from C26-WS, C26-MOD, and 695 
C26-SEV measured by fluorometry.  Differences determined by one-way ANOVA.  p<0.05 (*), p<0.01 (**). 696 
 697 
Figure 6.  Hepatic lipid peroxidation and oxidative stress in colon-26 tumor-induced cachexia. 698 
(a) Immunoblots showing 4-HNE formation in the full blot from 15-250 kDa probed in liver tissue homogenates.  699 
(b) 4-HNE formation in the full blot determined by expression of bands from 15-250 kDa normalized to GAPDH.  700 
(c) 4-HNE formation of bands from ~37-45 kDa normalized to GAPDH.  Data presented as mean ± SE.  701 
Tissues assayed from PBS Weight-Stable (n=4), C26 Weight-Stable (n=6), C26 Moderate (n=7), and C26 702 
Severe (n=6).  Differences determined by one-way ANOVA.  p<0.05 (*). 703 
 704 
Figure 7.  Loss of hepatic ACSL1 in colon-26 tumor-induced cachexia. 705 
(a) Immunoblots showing Acyl-CoA synthetase-1 (ACSL1) expression in liver tissue homogenates.  (b) ACSL1 706 
expression normalized to GAPDH.  Data presented as mean ± SE.  Tissues assayed from PBS Weight-Stable 707 
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(n=4), C26 Weight-Stable (n=6), C26 Moderate (n=7), and C26 Severe (n=6).  Differences determined by one-708 
way ANOVA.  p<0.05 (*), p<0.01 (**), p<0.001 (***).  (c) Associations of ACSL1 with percent body weight 709 
change, myofiber size, respiratory control ratio (RCR), and LEAK respiration in the complex I supported state 710 
normalized to maximal electron transfer system capacity (ETS).  Weight change, myofiber size, and respiration 711 
data were previously published (18) and used here for correlative purposes.  (d) Proposed mechanisms linking 712 
hepatic metabolism to cancer cachexia.  In response to tumor-secreted factors, the cachexic liver is subject to 713 
oxidative stress as indicated by greater 4-HNE formation, which could contribute to uncoupling of mitochondrial 714 
oxidative phosphorylation (OXPHOS) and lead to an increase in energy expenditure and weight loss.  The 715 
cachexic liver also shows decreased levels of ACSL1.  ACSL1 has been shown to protect against oxidative 716 
stress and positively influence mitochondrial function and coupling in several cell and disease models.  Loss of 717 
hepatic ACSL1 may therefore alter metabolism of the liver and contribute to cachexia-associated 718 
abnormalities. 719 
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Table 1.  Phenotype of mice with moderate and severe colon-26 tumor-induced cachexia 
 PBS Weight-Stable C26 Weight-Stable C26 Moderate Cachexia C26 Severe Cachexia  
Tumor weight (g) -- 0.4±0.1 ##, @@@ 1.1±0.1 @@@ 2.1±0.2  
Body weight change (%) 1±1 ###, @@@ 8±1 ###, @@@ -10±1 @@@ -22±2  
Quadriceps (mg) 166±10 #, @@ 164±7 #, @@ 132±9 121±4  
Plantaris (mg) 13.1±0.7 ##, @ 12.4±0.3 #, @ 10.0±0.7 10.3±0.4  
Gastrocnemius (mg) 112±2 ##, @@@ 110±3 ##, @@@ 90±3 84±4  
Fiber CSA (µm2) 1,965±126 ###, @@@ 1,758±189 ###, @@@ 994±37 820±105  
Epididymal fat (mg) 173±26 ### 183±12 ### 58±9 ND  
Spleen (mg) 89±4 ^, ## 128±7 155±8 119±12  
Liver (mg) 1,598±65 ##, @@ 1,607±41 ##, @@ 1,311±44 1,311±44  
The phenotype for this cohort of mice has been reported previously (18) and are provided here for descriptive purposes.  CSA, cross-
sectional area of the gastrocnemius.  ND, not detected.  n=4-7/group.  Data are mean ± SE.  Differences determined by one-way 
ANOVA.  P<0.05 (^) vs. C26 Weight-Stable.  P<0.05 (#), P<0.01 (##), P<0.001 (###) vs. C26 Moderate Cachexia.   P<0.05 (@), P<0.01 
(@@), P<0.001 (@@@) vs. C26 Severe Cachexia.   
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